• In recent months, Intuitive Surgical has faced FDA Class I recalls on certain da Vinci stapler components and visible institutional selling, raising concerns about product safety, regulatory scrutiny, and the resilience of its surgical robotics franchise.
• These events contrast with the company’s ongoing growth in da Vinci system installations and procedure volumes, sharpening the tension between operational momentum and rising risk perceptions among large investors.
• We’ll now explore how the FDA Class I recall, and the heightened focus on safety risk it brings, may reshape Intuitive Surgical’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Intuitive Surgical Investment Narrative Recap

To own Intuitive Surgical, you have to believe that robotic-assisted procedures and the da Vinci ecosystem will keep deepening their role in surgery, sustaining recurring instrument and service revenue. Right now, the key catalyst is continued growth in da Vinci installations and procedure volumes, while the biggest risk is rising regulatory and safety scrutiny around its instruments. The recent FDA Class I recall directly reinforces that risk, but so far has not visibly derailed near-term procedure or system growth.

In that context, the recent Q1 2026 earnings are especially important. Intuitive reported revenue of US$2,770.8 million and net income of US$821.5 million, both up from a year earlier, and continued to expand its installed base. This operational progress matters because it speaks directly to the core catalyst of higher procedure volumes, even as recalls, institutional selling, and valuation concerns test investor confidence in how durable that growth really is.

Yet beneath the strong top line, investors should be aware that regulatory and safety pressure on da Vinci instruments could...

Intuitive Surgical's narrative projects $13.4 billion revenue and $3.7 billion earnings by 2028. This requires 13.5% yearly revenue growth and about a $1.1 billion earnings increase from $2.6 billion today.

Uncover how Intuitive Surgical's forecasts yield a $611.82 fair value, a 42% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this recall, expecting revenue to reach about US$16.1 billion and earnings US$4.9 billion by 2029, which shows how differently you and other investors might weigh upside from faster da Vinci 5 adoption against heightened regulatory risk after a Class I safety event.

Explore 13 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 46% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.